Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)
 
 • Company Description   
Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.

Number of Employees: 87

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.57 Daily Weekly Monthly
20 Day Moving Average: 77,153 shares
Shares Outstanding: 26.73 (millions)
Market Capitalization: $336.02 (millions)
Beta: 0.69
52 Week High: $19.66
52 Week Low: $10.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.22% -21.73%
12 Week -13.61% -19.94%
Year To Date -14.26% -18.15%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15440 LAGUNA CANYON ROAD SUITE 160
-
IRVINE,CA 92618
USA
ph: 949-409-9820
fax: -
ir@tarsusrx.com http://www.tarsusrx.com
 
 • General Corporate Information   
Officers
Bobak Azamian - President; Chief Executive Officer and Chairman
Leonard M. Greenstein - Chief Financial Officer
Scott Morrison - Director
Bhaskar Chaudhuri - Director
Rosemary Crane - Director

Peer Information
Tarsus Pharmaceuticals, Inc. (CORR.)
Tarsus Pharmaceuticals, Inc. (RSPI)
Tarsus Pharmaceuticals, Inc. (CGXP)
Tarsus Pharmaceuticals, Inc. (BGEN)
Tarsus Pharmaceuticals, Inc. (GTBP)
Tarsus Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87650L103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 05/09/23
Share - Related Items
Shares Outstanding: 26.73
Most Recent Split Date: (:1)
Beta: 0.69
Market Capitalization: $336.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.94 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.82 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/09/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.74
Price/Cash Flow: -
Price / Sales: 19.32
EPS Growth
vs. Year Ago Period: 31.94%
vs. Previous Quarter: 41.67%
Sales Growth
vs. Year Ago Period: 2,858.58%
vs. Previous Quarter: -%
ROE
03/31/23 - -32.41
12/31/22 - -34.24
09/30/22 - -31.56
ROA
03/31/23 - -27.64
12/31/22 - -29.82
09/30/22 - -28.14
Current Ratio
03/31/23 - 14.61
12/31/22 - 16.40
09/30/22 - 21.36
Quick Ratio
03/31/23 - 14.61
12/31/22 - 16.40
09/30/22 - 21.36
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -324.99
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -324.99
Pre-Tax Margin
03/31/23 - -240.53
12/31/22 - -351.71
09/30/22 - -326.64
Book Value
03/31/23 - 7.23
12/31/22 - 7.60
09/30/22 - 10.69
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.10
12/31/22 - 0.10
09/30/22 - 0.09
Debt-to-Capital
03/31/23 - 9.15
12/31/22 - 8.72
09/30/22 - 8.00
 

Powered by Zacks Investment Research ©